Starling Oncology, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $169.8 million (+24.3% year over year) and diluted EPS of -$0.13. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
170
+24.3%
|
-16
+4.6%
|
-0.13
+7.1%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
161
+34.6%
|
-10
+42.4%
|
-0.08
+46.7%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
147
+41.2%
|
-2
+87.3%
|
-0.02
+90.5%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
142
+41.6%
|
-8
+43.0%
|
-0.06
+55.7%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
137
+36.7%
|
-17
-2.4%
|
-0.14
+22.2%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
120
+21.5%
|
-17
-9.9%
|
-0.15
+11.8%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
104
+10.3%
|
-20
+1.5%
|
-0.21
+4.5%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
100
+21.8%
|
-16
+7.5%
|
-0.18
+5.3%
|
Company profile
- Industry
- Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
- Listed as
- STLN (Nasdaq), DFPH (OTC), STLNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1799191
- Former names
- Oncology Institute, Inc. (until Aug 3, 2026); DFP HEALTHCARE ACQUISITIONS CORP. (until Nov 12, 2021)
Other Services-Offices & Clinics of Doctors of Medicine companies
- Hims & Hers Health, Inc. HIMS
- Teladoc Health, Inc. TDOC
- SBC Medical Group Holdings Inc SBC
- Auna S.A. AUNA
- Airsculpt Technologies, Inc. AIRS
- LifeMD, Inc. LFMD
- Westin Acquisition Corp WSTN
- Basel Medical Group Ltd BMGL
All 12 Services-Offices & Clinics of Doctors of Medicine companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.